Masaru Matsuda, See Remarks at Arcutis Biotherapeutics, Inc. (ARQT), sold 5,030 shares at $15.20 ($76K) on 2025-05-02, disclosed to the SEC on 2025-05-05.
Scheduled sale ($76k) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARQT | SELL | 2026-08-05 | $32K | — | Filing → |
| ARQT | SELL | 2026-05-06 | $192K | — | Filing → |
| ARQT | SELL | 2026-03-03 | $314K | — | Filing → |